Ozempic

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs. What Happened: During a confidential meeting, Trump alerted drug companies about the impending tariffs, urging...

Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country with surprisingly big economic power. While Denmark might not have a military capable of standing up to the U.S., it has something just as powerful—control over key products...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with the Senate Finance Committee. While Kennedy’s tone in each back-and-forth varied, depending on the senator, it was...

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:NVO), for the treatment of chronic kidney disease in patients who also have type 2 diabetes.  The Details: According to the Centers for Disease Control and Prevention, more than 35.5...

The world’s richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro. What Happened: Musk on Christmas posted a picture of himself donning the Santa Claus costume with the caption “Ozempic Santa.” Ozempic Santa pic.twitter.com/7YECSNpWoz —...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

The debate over how to tackle America's obesity epidemic that affects 40% of adults and nearly 20% of children, has sparked contrasting views from two influential voices in President-elect Donald J. Trump's orbit. The side that wins could have a lasting impact on public health in the U.S....

The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordisk A/S (NYSE:NVO) has faced backlash for the steep prices of Wegovy and Ozempic, two popular drugs...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 weight-loss drugs like Ozempic. What Happened: Jan Hatzius, chief economist at Goldman Sachs, has said that US GDP could potentially grow an additional 1% if 60 million...

Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects. What Happened: The Danish pharmaceutical giant is contending with rivals like Eli Lilly & Co...

Hims & Hers Health Inc. (NYSE:HIMS) shares fell Wednesday following an FDA update listing Novo Nordisk’s (NYSE:NVO) diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here’s what you need to know. What Happened: A report from the FDA...

Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper alternatives have been under scrutiny due to potential safety risks and lack of FDA approval....

Novo Nordisk A/S (NYSE:NVO) just hit a technical red flag — a Death Cross. Chart created using Benzinga Pro For those uninitiated, this bearish signal occurs when a stock's 50-day moving average drops below its 200-day moving average, hinting that more downside could be ahead. However, Novo...

A recent real-world data analysis was conducted to suggest a link between glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) prescriptions and reduced rates of opioid overdose and alcohol intoxication among patients with opioid use disorder (...

The Federal Reserve's preferred measure of inflation, the personal consumption expenditures index, grew less than economists expected in August at 2.2% year-over-year. The data comes on the heels of the Federal Reserve's 0.5% interest rate cut issued Sept. 18, the first in more than four years....